Merck & Company Inc (MRK)vsProMIS Neurosciences Inc. (PMN)
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
PMN
ProMIS Neurosciences Inc.
$9.13
-6.17%
HEALTHCARE · Cap: $91.02M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 869947016% more annual revenue ($65.77B vs $7,560). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
PMN
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for PMN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PMN
The strongest argument for PMN centers on Price/Book.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : PMN
The primary concerns for PMN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →ProMIS Neurosciences Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
ProMIS Neurosciences Inc. is an innovative biotechnology firm dedicated to developing groundbreaking therapeutic solutions for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Leveraging its proprietary protein engineering platform, the company excels in identifying and targeting misfolded proteins linked to these conditions, positioning its drug candidates to offer enhanced safety and efficacy. With a robust pipeline at various stages of development, ProMIS is strategically positioned to advance critical neurotherapeutic options that address significant unmet medical needs in the biopharmaceutical landscape, making it an appealing prospect for institutional investors seeking growth in the healthcare sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?